An unbiased high‐throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer‐related deaths in the United States by 2020, due in part to innate resistance to widely used chemotherapeutic agents and limited knowledge about key molecular factors that drive tumor aggression. We pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Chun‐Hao, Otsuka, Yuka, Sridharan, BanuPriya, Woo, Melissa, Leiton, Cindy V., Babu, Sruthi, Torrente Gonçalves, Mariana, Kawalerski, Ryan R., K. Bai, Ji Dong, Chang, David K., Biankin, Andrew V., Scampavia, Louis, Spicer, Timothy, Escobar‐Hoyos, Luisa F., Shroyer, Kenneth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400780/
https://www.ncbi.nlm.nih.gov/pubmed/32533886
http://dx.doi.org/10.1002/1878-0261.12743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400780/
https://www.ncbi.nlm.nih.gov/pubmed/32533886
http://dx.doi.org/10.1002/1878-0261.12743

Ejemplares similares